Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis

Blood

Volumn 122, Issue 25, 2013, Pages 4107-4110

  McGrath, Rachel T ^a   Van Den Biggelaar, Maartje ^b   Byrne, Barry ^c   O’Sullivan, Jamie M ^a   Rawley, Orla ^a   O’Kennedy, Richard ^c   Voorberg, Jan ^b   Preston, Roger J S ^d   O’Donnell, James S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b SANQUIN RESEARCH   (Netherlands)

^c DUBLIN CITY UNIVERSITY   (Ireland)

^d OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; BLOOD GROUP ABO SYSTEM;

ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; EMBRYO; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRECURSOR; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; SIALYLATION; THROMBOCYTE; THROMBOCYTE ACTIVATION; BIOSYNTHESIS; BLOOD CLOTTING; BLOOD GROUP ABO SYSTEM; CHEMISTRY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; METABOLISM; PHYSIOLOGY; SECRETORY VESICLE;

ABO BLOOD-GROUP SYSTEM; ADAM PROTEINS; BLOOD COAGULATION; BLOOD PLATELETS; GENE EXPRESSION REGULATION; GLYCOSYLATION; HEK293 CELLS; HUMANS; PLATELET ACTIVATION; PROTEOLYSIS; SECRETORY VESICLES; VON WILLEBRAND FACTOR;

EID: 84891120182     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-496851     Document Type: Article

References (25)

1. Howard MA, Montgomery DC, Hardisty RM. Factor-VIII-related antigen in platelets. Thromb Res. 1974;4(5):617-624.
2. Nachman RL, Jaffe EA. Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med. 1975;141(5):1101-1113.
3. Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci USA. 1995;92(7):2428-2432.
4. McGrath RT, McRae E, Smith OP, O’Donnell JS. Platelet von Willebrand factor—structure, function and biological importance. Br J Haematol. 2010; 148(6):834-843.
5. Sultan Y, Jeanneau C, Lamaziere J, Maisonneuve P, Caen JP. Platelet factor VIII-related antigen: studies in vivo after transfusion in patients with von Willebrand disease. Blood. 1978;51(4): 751-761.
6. Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980;65(6):1318-1325.
7. Fressinaud E, Baruch D, Rothschild C, Baumgartner HR, Meyer D. Platelet von Willebrand factor: evidence for its involvement in platelet adhesion to collagen. Blood. 1987;70(4): 1214-1217.
8. Bowie EJ, Solberg LA Jr, Fass DN, et al. Transplantation of normal bone marrow into a pig with severe von Willebrand’s disease. J Clin Invest. 1986;78(1):26-30.
9. Nichols TC, Bellinger DA, Reddick RL, et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood. 1993;81(10):2644-2651.
10. Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012;10(8): 1646-1652.
11. Williams SB, McKeown LP, Krutzsch H, Hansmann K, Gralnick HR. Purification and characterization of human platelet von Willebrand factor. Br J Haematol. 1994;88(3):582-591.
12. Canis K, McKinnon TAJ, Nowak A, et al. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost. 2010;8(1):137-145.
13. Canis K, McKinnon TA, Nowak A, et al. Mapping the N-glycome of human von Willebrand factor. Biochem J. 2012;447(2):217-228.
14. Kagami K, Williams S, Horne M, Gralnick H. A preliminary analysis of platelet von Willebrand factor oligosaccharides. Nagoya J Med Sci. 2000; 63(1-2):51-56.
15. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003;1(1): 33-40.
16. O’Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 2005;106(6):1988-1991.
17. McKinnon TAJ, Chion ACK, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111(6):3042-3049.
18. McGrath RT, McKinnon TA, Byrne B, et al. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood. 2010;115(13): 2666-2673.
19. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103(6):2096-2104.
20. van den Biggelaar M, Meijer AB, Voorberg J, Mertens K. Intracellular cotrafficking of factor VIII and von Willebrand factor type 2N variants to storage organelles. Blood. 2009;113(13): 3102-3109.
21. O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22(2):335-341.
22. Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost. 2002;87(6):990-996.
23. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA. 2002;99(15):10042-10047.
24. van Schooten CJ, Denis CV, Lisman T, et al. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood. 2007; 109(6):2430-2437.
25. Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008;14(6): 648-655.